Document is current
Any future updates will be listed below
-
Authors
Toto, Neema
Douglas, Elaine
Gmeiner, Markus
Barrett, Lynn K.
Lindblad, Robert
Makhaza, Lumbani
Nedi, Wilfred
Phulusa, Jacob
Quinnan, Gerald V.
Sawyer, Leigh A.
Thole, Herbert
Van Voorhis, Wesley C.
Iroh Tam, Pui-Ying http://orcid.org/0000-0002-3682-8892
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1172544)
- License Information
-
More Information
Article History
Received: 5 March 2020
Accepted: 16 July 2020
First Online: 25 July 2020
Ethics approval and consent to participate
: This manuscript does not directly contain human data; however, its topic is a clinical trial in which all patients were appropriately consented and ethics approval was granted from the NHSRC (reference 17/05/1821) and by the Liverpool School of Tropical Medicine Research Ethics Committee (reference 17-031).
: There was no specific informed consent sought for this publication because it does not contain any patient data. However, as part of the Cryptofaz clinical trial, full informed consent was obtained before any patient started the study.
: PI and WVV have received grants from Bill & Melinda Gates Foundation (BMGF) outside of the submitted work. WVV has patents issued for bumped kinase inhibitors (BKIs) for the therapeutic treatment of cryptosporidiosis diarrhea and is a founder and has stock of ParaTheraTech LLC, a company that is developing BKIs for animal health indications. All other authors declare no competing interests.
